VAXCYTE INC's ticker is PCVX and the CUSIP is 92243G108. A total of 87 filers reported holding VAXCYTE INC in Q1 2022. The put-call ratio across all filers is - and the average weighting 0.9%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $422,330,861 | +2.7% | 8,284,246 | +0.6% | 0.01% | 0.0% |
| Q2 2023 | $411,324,518 | +68.0% | 8,236,374 | +26.1% | 0.01% | +66.7% |
| Q1 2023 | $244,831,203 | -22.8% | 6,532,316 | -1.2% | 0.01% | -33.3% |
| Q4 2022 | $317,125,284 | +196.8% | 6,613,666 | +48.6% | 0.01% | +200.0% |
| Q3 2022 | $106,851,000 | +24.1% | 4,452,145 | +12.5% | 0.00% | +50.0% |
| Q2 2022 | $86,081,000 | -1.8% | 3,955,918 | +9.0% | 0.00% | 0.0% |
| Q1 2022 | $87,649,000 | +17.5% | 3,629,364 | +15.8% | 0.00% | 0.0% |
| Q4 2021 | $74,565,000 | -3.4% | 3,134,286 | +3.0% | 0.00% | 0.0% |
| Q3 2021 | $77,224,000 | +20.4% | 3,043,882 | +6.9% | 0.00% | 0.0% |
| Q2 2021 | $64,123,000 | +17.2% | 2,848,644 | +2.8% | 0.00% | +100.0% |
| Q1 2021 | $54,734,000 | +42.1% | 2,771,314 | +91.2% | 0.00% | 0.0% |
| Q4 2020 | $38,510,000 | -42.4% | 1,449,377 | +7.1% | 0.00% | -50.0% |
| Q3 2020 | $66,802,000 | +6946.6% | 1,352,820 | +4409.4% | 0.00% | – |
| Q2 2020 | $948,000 | – | 30,000 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Abingworth LLP | 4,168,718 | $82,124,000 | 28.36% |
| Medicxi Ventures Management (Jersey) Ltd | 1,887,478 | $37,277,000 | 21.71% |
| Pivotal bioVenture Partners Investment Advisor LLC | 1,405,421 | $27,757,000 | 8.90% |
| FRAZIER MANAGEMENT LLC | 2,309,554 | $45,614,000 | 3.66% |
| RA Capital Management | 3,865,808 | $76,350,000 | 1.15% |
| TPG Group Holdings (SBS) Advisors, Inc. | 4,558,475 | $90,030,000 | 1.05% |
| Soleus Capital Management, L.P. | 293,650 | $5,800,000 | 1.04% |
| Opaleye Management Inc. | 357,800 | $7,067,000 | 1.04% |
| SABBY MANAGEMENT, LLC | 178,992 | $3,535,000 | 0.69% |
| Penn Mutual Asset Management | 22,227 | $439,000 | 0.50% |